NDAORALTABLET
Approved
Sep 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 37m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
WYTENSIN (guanabenz acetate) is an oral antihypertensive tablet approved in 1982 that acts as a centrally-acting alpha-2 adrenergic agonist. It is indicated for the treatment of hypertension, typically used as monotherapy or in combination with other antihypertensive agents. The drug works by stimulating alpha-2 receptors in the central nervous system to reduce sympathetic outflow and lower blood pressure.
LOE Approaching
With LOE approaching and low competitive pressure (30), this product faces declining market relevance and smaller team footprint.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on WYTENSIN offers limited career growth given its approaching LOE and minimal linked job openings (0 current positions). This is a declining franchise with shrinking team structures and reduced marketing investment, best suited for professionals managing legacy products or transitioning portfolios.
Brand ManagerField Sales Representative
Worked on WYTENSIN at Thayer Medical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.